BioBlock® nasal spray is a natural product that contains antibodies against SARS-CoV-2 along with naturally occurring beneficial antibodies in colostrum which humans benefit daily while consuming dairy and meat products. In vitro testings demonstrated that the product blocks the entry of viral particles into cells.
Tests were performed against initial Wuhan and newly mutated SARS-CoV-2 variants – Omicron B.1.1.529 (incl. its sublineages BA.1, BA.2, BA.4, BA.5, BA.2.75.2 and BA.2.3.20), Indian (Delta B.1.617.2, Kappa B.1.617.1), UK B.1.1.7, South African B.1.351 and Brazil P.1.
BioBlock® can be used wherever it is difficult to distance from others: at home, at work, at school, in gyms, in public transportation and in crowded places. This natural product does not cause dryness of nasal mucous membrane.
BioBlock® is not a medicine.
2 sprays into each nostril, 3-4 times a day, and before and after visiting crowded places. After blowing the nose, it is recommended to use the spray again.
BioBlock® is effective on the nasal mucosa up to 4 hours.
The product contains 150 spray doses.
Store at room temperature. After first usage utilize within 3 months. Best before presented on the package.
BioBlock® contains 15 ml of solution.
Bovine colostrum derived SARS-CoV-2 antibodies (0.2 mg/ml)
Phosphate buffer: DPBS (without Ca and Mg salts)
Viscosity enhancing compounds: PEG400, PVP K30
Preservative: sodium benzoate
Acidity regulator: citric acid
Mucous membrane moisturizing compound: glycerol
Potassium chloride – buffer component
Potassium dihydrogen phosphate – buffer component
Sodium chloride – buffer component
Disodium phosphate – buffer component
Product does not contain lactose.
Warnings and precautions
Do not use if allergic to milk proteins or to any of the other ingredients in this product (especially under 6 y/o children).
If pregnant, breast-feeding or before using the product for and by children, contact your healthcare professional.
Do not exceed the stated daily dose. Keep this product out of reach of children.
A USPTO patent application (No. 63/160,833) has been submit- ted by the product developers.
Tänassilma road 11, Tänassilma 76406 Harju county, Estonia, EU
University of Tartu (Institute of Technology, Institute of Pharmacy, Institute of Biomedicine and Translational Medicine)
Institute of Veterinary Medicine and Animal Sciences of the Estonian University of Life Sciences
OÜ Teadus ja Tegu
Icosagen Cell Factory OÜ